Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on July 28, 2021, to provide updated financial information related to its prospectus and a preliminary range of financial results for the six months ended June 30, 2021. The company is preparing to list on the STAR Market in China and has provided R&D expenses by key products and other projects for 2018-2020, prepared under PRC GAAP. Investors should note that the preliminary financial results for H1 2021 have not been audited and are subject to change. The filing also includes forward-looking statements concerning the proposed RMB share issuance, highlighting that this offering is contingent on market conditions and regulatory approvals, and there is no certainty it will proceed. Shareholders are advised to exercise caution.
Key Highlights
- 1BeOne Medicines Ltd. provided preliminary financial results for the six months ended June 30, 2021, which include total revenue and net loss attributable to the Company.
- 2These preliminary results were prepared in accordance with PRC GAAP and have not been audited or reviewed by independent accountants.
- 3The company also disclosed detailed R&D expenses allocated by key products and other projects for the years 2018, 2019, and 2020, prepared under PRC GAAP.
- 4The filing discusses a proposed issuance of RMB Shares to be listed on the STAR Market, subject to market conditions and necessary regulatory approvals.
- 5There is a risk that the proposed RMB share issuance may not materialize or could be delayed.
- 6The company emphasizes that the information provided is for informational purposes and does not constitute an offer to buy or sell securities.
- 7Investors are cautioned about the uncertainty of the RMB share issuance and advised to exercise caution when dealing with the company's securities.